OptiBiotix Health PLC Issue of Equity -- Subscription (5174I)

TIDMOPTI

RNS Number : 5174I

OptiBiotix Health PLC

05 December 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Issue of Equity - Subscription

Appointment of Joint Broker

OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, cardiovascular disease, diabetes and skincare, a nnounces that the Company has raised GBP500,000 through the issue of 3,125,000 new ordinary shares of 2 pence each in the Company ("Ordinary Shares") at a price of 16 pence per share (the "Subscription") handled by Peterhouse Capital Limited.

The net proceeds of the Subscription will be utilised to invest in the Company's direct-to-consumer ("D2C") product model, in particular to drive sales growth across the business and build partnerships in the USA and for general working capital purposes.

Appointment of Joint Broker

Separately, the Company announces the appointment of Peterhouse Capital Limited as joint broker to the Company with immediate effect.

Admission

Application will be made to the London Stock Exchange to admit the 3,125,000 new Ordinary Shares to trading on AIM ("Admission"). Admission of the new Ordinary Shares is expected to occur on or around 9 December 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 91,190,661 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

Stephen O'Hara, CEO of OptiBiotix, commented: " I am pleased with the interest shown from new and existing shareholders in this fundraise which will support further company growth. The funds will support an acceleration of our direct to consumer business, help expand our US partner network, and launch our second generation products into the market. These steps will help create shareholder value and support OptiBiotix's position as a leader in the microbiome field."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
  OptiBiotix Health plc                              www.optibiotix.com 
  Neil Davidson, Chairman                          Contact via Walbrook 
                                                                  below 
  Stephen O'Hara, Chief Executive 
 
  Cairn Financial Advisers LLP (NOMAD)               Tel: [phone] 
  Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
  Cenkos Securities plc ( Joint Broker)              Tel: [phone] 
  Callum Davidson 
  Michael Johnson / Russell Kerr (Sales) 
 
  Peterhouse Capital Limited (Joint Broker)          Tel: [phone] 
  Duncan Vasey/ Lucy Williams 
  Walbrook PR Ltd                                    Mob: [phone] 
  Anna Dunphy 
 
 
   About OptiBiotix   -   www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiÞed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reßect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEZZMGZRFZGZZM

(END) Dow Jones Newswires

December 05, 2022 02:00 ET (07:00 GMT)